From bench to almost bedside: the long road to a licensed Ebola virus vaccine

References

• Feldmann H, Sanchez A, Geisbert TW. Filoviridae: marburg and Ebola viruses. Knipe DM, Howley P, editors. Philadelphia, PA: USA: Lippincott Williams and Wilkins. 2013. Fields Virology.
   Google Scholar
• Nkoghe D, Leroy EM, Toung-Mve M, et al. Cutaneous manifestations of filovirus infections [Review]. Int J Dermatol. 2012 Sep;51(9):1037–1043. PubMed PMID: 22909355; eng. DOI:10.1111/j.1365-4632.2011.05379.x
   PubMed Web of Science ®Google Scholar
• Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999 Feb;179(Suppl 1):S28–35. PubMed PMID: 9988162; eng. DOI:10.1086/514318
   PubMed Web of Science ®Google Scholar
• Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999 Feb;179(Suppl 1):S170–6. PubMed PMID: 9988181; eng. DOI:10.1086/514291
   PubMed Web of Science ®Google Scholar
• Anonymous. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. Bull World Health Organ. 1978;56(2):271–293. PubMed PMID: 307456; PubMed Central PMCID: PMC2395567. eng.
   PubMed Web of Science ®Google Scholar
• Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005 Dec 1;438(7068):575–576. PubMed PMID: 16319873; eng. DOI:10.1038/438575a
   PubMed Web of Science ®Google Scholar
• Previous Updates: 2014 West Africa Outbreak (February 25, 2015). Centers for Disease Control and Prevention. 2015. Available at: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/previous-updates.html Last accessed 2017 Nov 8
   Google Scholar
• Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea [Research Support, Non-U.S. Gov’t]. N Engl J Med. 2014 Oct 09;371(15):1418–1425. PubMed PMID: 24738640; eng. DOI:10.1056/NEJMoa1404505
   PubMed Web of Science ®Google Scholar
• Nigeria is now free of Ebola virus transmission. World Health Organization. 2014. Available from: http://www.who.int/mediacentre/news/ebola/20-october-2014/en/index2.html Last accessed 2017 Nov 8.
   Google Scholar
• The outbreak of Ebola virus disease in Senegal is over. World Health Organization. 2014. Available from: http://www.who.int/mediacentre/news/ebola/17-october-2014/en/[Last accessed 2017 Nov 8.
   Google Scholar
• New York City Reports Positive Test for Ebola in Volunteer International Aid Worker. Centers for Disease Control and Prevention. 2014. Available from: http://www.cdc.gov/media/releases/2014/s1023-ebola-nyc.html Last accessed 2017 Nov 8.
   Google Scholar
• EBOLA UPDATE (03): AFRICA, WORLD, USA, UK, SUSPECTED, DRUGS, VACCINES. ProMED mail. 2015. Available from: http://www.promedmail.org/direct.php?id=3069311 Last accessed 2017 Nov 8
   Google Scholar
• EBOLA VIRUS DISEASE - ex AFRICA (27): USA (TEXAS) SECOND NURSE BETTER, TEST, QUARANTINE. ProMED mail. 2014. Available from: http://www.promedmail.org/direct.php?id=2910297 Last accessed 2017 Nov 8
   Google Scholar
• EBOLA VIRUS DISEASE - ex AFRICA (32): SPANISH NURSE RECOVERED, USA SEEKS PATENT. ProMED mail. 2014. Available from: http://www.promedmail.org/direct.php?id=2939861 Last accessed 2017 Nov 8
   Google Scholar
• Ebola Situation Report - 26 May 2016. World Health Organization. 2016. Available from: http://apps.who.int/iris/bitstream/10665/206924/1/ebolasitrep_26May2016_eng.pdf?ua=1 Last accessed 2017 Nov 8.
   Google Scholar
• Meltzer MI, Atkins CY, Santibanez S, et al. Estimating the future number of cases in the Ebola epidemic–liberia and Sierra Leone, 2014-2015. MMWR Surveill Summ. 2014 Sep 26;63(Suppl 3):1–14. PubMed PMID: 25254986; eng.
   Google Scholar
• Bol GF. Risk communication in times of crisis: pitfalls and challenges in ensuring preparedness instead of hysterics. EMBO Rep. 2016 Jan;17(1):1–9. PubMed PMID: 26658329; PubMed Central PMCID: PMC4718415. eng. DOI:10.15252/embr.201541678
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Moore KA, Kelley NS, et al. Transmission of ebola viruses: what we know and what we do not know. MBio. 2015;6(2). PubMed PMID: 25698835; eng. 10.1128/mBio.00137-15
   Web of Science ®Google Scholar
• Guidance for industry—product development under the animal rule. US Food and Drug Administration. 2014. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf Last accessed 2017 Nov 8
   Google Scholar
• Bray M, Davis K, Geisbert T, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [Research Support, U.S. Gov’t, Non-P.H.S.]. J Infect Dis. 1998 Sep;178(3):651–661. PubMed PMID: 9728532; eng.
   PubMed Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999 Feb;179(Suppl 1):S203–17. PubMed PMID: 9988186; eng. DOI:10.1086/514305
   PubMed Web of Science ®Google Scholar
• Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol. 2013;4:267. PubMed PMID: 24046765; PubMed Central PMCID: PMC3763195. eng. DOI:10.3389/fmicb.2013.00267
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of ebola virus and marburg virus infection. J Infect Dis. 2015 Oct 01;212(Suppl 2):S91–7. PubMed PMID: 26063223; PubMed Central PMCID: PMC4564553. Doi:10.1093/infdis/jiv284
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 Nov 30;408(6812):605–609. PubMed PMID: 11117750; eng. DOI:10.1038/35046108
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003 Aug 07;424(6949):681–684. PubMed PMID: 12904795; eng. DOI:10.1038/nature01876
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006 Jun;3(6):e177. PubMed PMID: 16683867; PubMed Central PMCID: PMC1459482. eng. DOI:10.1371/journal.pmed.0030177
   PubMed Web of Science ®Google Scholar
• Wu S, Kroeker A, Wong G, et al. An adenovirus vaccine expressing ebola virus variant makona glycoprotein is efficacious in guinea pigs and nonhuman primates. J Infect Dis. 2016 Aug 4 PubMed PMID: 27493239; Eng. DOI:10.1093/infdis/jiw250
   Web of Science ®Google Scholar
• Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet. 2000 Nov 1;(2):91–99. PubMed PMID: 11253666; eng. Doi:10.1038/35038533
   PubMed Web of Science ®Google Scholar
• Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999 Sep;6(9):1574–1583. PubMed PMID: 10490767; eng. DOI:10.1038/sj.gt.3300994
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010 Jan 22;28(4):950–957. S0264-410X(09)01728-9 [pii]. PubMed PMID: 19925902; eng. DOI:10.1016/j.vaccine.2009.10.145
   PubMed Web of Science ®Google Scholar
• Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States [Research Support, U.S. Gov’t, P.H.S.]. Clin Diagn Lab Immunol. 2004 Mar;11(2):351–357. PubMed PMID: 15013987; PubMed Central PMCID: PMC371218. eng.
   PubMedGoogle Scholar
• Cheng C, Wang L, Gall JG, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PloS One. 2012;7(4):e33969. PONE-D-11-21868 [pii]. PubMed PMID: 22496775; PubMed Central PMCID: PMC3319553. eng. DOI:10.1371/journal.pone.0033969
   PubMed Web of Science ®Google Scholar
• Richardson JS, Pillet S, Bello AJ, et al. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates [Comparative Study Research Support, Non-U.S. Gov’t]. J Virol. 2013 Apr;87(7):3668–3677. PubMed PMID: 23302894; PubMed Central PMCID: PMC3624216. eng. DOI:10.1128/JVI.02864-12
   PubMed Web of Science ®Google Scholar
• Choi JH, Jonsson-Schmunk K, Qiu X, et al. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Mol Pharm. 2014 Nov 14 PubMed PMID: 25363619; eng. DOI:10.1021/mp500646d
   Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Adenovirus-vectored vaccine provides post-exposure protection to Ebola virus-infected nonhuman primates. J Infect Dis. 2015 Oct 1;212(Suppl 2):S379–83. PubMed PMID: 25957963; PubMed Central PMCID: PMC4564535; eng. DOI:10.1093/infdis/jiv102
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011 May;85(9):4222–4233. PubMed PMID: 21325402; PubMed Central PMCID: PMC3126236; eng.
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006 Mar 15;346(2):394–401. PubMed PMID: 16356525; eng. DOI:10.1016/j.virol.2005.10.042
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine. 2014 Oct;20(10):1126–1129. PubMed PMID: 25194571; eng.
   PubMed Web of Science ®Google Scholar
• Brandly CA, Hanson RP. Epizootiology of vesicular stomatitis. Am J Public Health Nations Health. 1957 Feb;47(2):205–209. PubMed PMID: 13394773; PubMed Central PMCID: PMC1551163. eng.
   PubMed Web of Science ®Google Scholar
• Brody JA, Fischer GF, Peralta PH. Vesicular stomatitis virus in Panama. Human serologic patterns in a cattle raising area. Am J Epidemiol. 1967 Jul;86(1):158–161. PubMed PMID: 4378113; eng.
   PubMed Web of Science ®Google Scholar
• Johnson KM, Vogel JE, Peralta PH. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg. 1966 Mar;15(2):244–246. PubMed PMID: 4286381; eng.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Nature Medicine. 2005 Jul;11(7):786–790. PubMed PMID: 15937495; eng.
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection [Clinical Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. PLoS Pathogens. 2007 Jan;3(1):e2. PubMed PMID: 17238284; PubMed Central PMCID: PMC1779298. eng. DOI:10.1371/journal.ppat.0030002
   PubMed Web of Science ®Google Scholar
• Marzi A, Robertson SJ, Haddock E, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t]. Science. 2015 Aug 14;349(6249):739–742. PubMed PMID: 26249231; eng. DOI:10.1126/science.aab3920
   PubMed Web of Science ®Google Scholar
• Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents [Research Support, Non-U.S. Gov’t]. Vaccine. 2014 Sep 29;32(43):5722–5729. PubMed PMID: 25173474; eng. DOI:10.1016/j.vaccine.2014.08.028
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Agans KN, et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. PloS One. 2014;9(4):e94355. PubMed PMID: 24759889; PubMed Central PMCID: PMC3997383. eng. DOI:10.1371/journal.pone.0094355
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural]. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893–1898. PubMed PMID: 23319647; PubMed Central PMCID: PMC3562844. eng. DOI:10.1073/pnas.1209591110
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates [Research Support, Non-U.S. Gov’t]. Sci Transl Med. 2012 Oct 31;4(158):158ra146. PubMed PMID: 23115355; PubMed Central PMCID: PMC3789651. eng. DOI:10.1126/scitranslmed.3004582
   PubMed Web of Science ®Google Scholar
• Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology. 2007 Mar 30;360(1):36–49. PubMed PMID: 17098273; PubMed Central PMCID: PMC1865117. eng. DOI:10.1016/j.virol.2006.10.026
   PubMed Web of Science ®Google Scholar
• Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6(3):e1567. PNTD-D-11-00959 [pii]. PubMed PMID: 22448291; PubMed Central PMCID: PMC3308941. eng. DOI:10.1371/journal.pntd.0001567
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. PLoS Pathogens. 2008 Nov;4(11):e1000225. PubMed PMID: 19043556; PubMed Central PMCID: PMC2582959. eng. DOI:10.1371/journal.ppat.1000225
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge [Research Support, Non-U.S. Gov’t]. J Infect Dis. 2007 Nov 15;196(Suppl 2):S430–7. PubMed PMID: 17940980; eng. DOI:10.1086/520583
   PubMed Web of Science ®Google Scholar
• Warfield KL, Goetzmann JE, Biggins JE, et al. Vaccinating captive chimpanzees to save wild chimpanzees [Research Support, Non-U.S. Gov’t]. Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8873–8876. PubMed PMID: 24912183; PubMed Central PMCID: PMC4066532. eng. DOI:10.1073/pnas.1316902111
   PubMed Web of Science ®Google Scholar
• Denny FW, Clyde WA. Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr. 1986 May;108(5 Pt 1):635–646. PubMed PMID: 3009769; eng.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus [Research Support, N.I.H., Intramural]. J Virol. 2007 Jun;81(12):6379–6388. PubMed PMID: 17428868; PubMed Central PMCID: PMC1900097. eng.
   PubMed Web of Science ®Google Scholar
• Bukreyev AA, Dinapoli JM, Yang L, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010 Apr 10;399(2):290–298. S0042-6822(10)00032-2 [pii]. PubMed PMID: 20129638; PubMed Central PMCID: PMC2842940. eng. DOI:10.1016/j.virol.2010.01.015
   PubMed Web of Science ®Google Scholar
• Taylor KG. Paessler S. Pathogenesis of Venezuelan equine encephalitis. Vet Microbiol. 2013 Nov 29;167(1–2):145–150. S0378-1135(13)00374-X [pii]. PubMed PMID: 23968890; eng. Doi:10.1016/j.vetmic.2013.07.012
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998 Nov 10;251(1):28–37. PubMed PMID: 9813200; eng. DOI:10.1006/viro.1998.9367
   PubMed Web of Science ®Google Scholar
• Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013 May;87(9):4952–4964. PubMed PMID: 23408633; PubMed Central PMCID: PMC3624300. eng.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095–2128. S0140-6736(12)61728-0 [pii]. PubMed PMID: 23245604; eng. DOI:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Cliquet F, Aubert M. Elimination of terrestrial rabies in Western European countries. Dev Biol (Basel). 2004;119: 185–204. PubMed PMID: 15747421; eng.
   PubMedGoogle Scholar
• Cliquet F, Robardet E, Must K, et al. Eliminating rabies in Estonia. PLoS Negl Trop Dis. 2012;6(2):e1535. PNTD-D-11-00678 [pii]. PubMed PMID: 22393461; PubMed Central PMCID: PMC3289618. eng. DOI:10.1371/journal.pntd.0001535
   PubMed Web of Science ®Google Scholar
• Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural]. PLoS Pathogens . 2013;9(5):e1003389. PubMed PMID: 23737747; PubMed Central PMCID: PMC3667758. eng. DOI:10.1371/journal.ppat.1003389.
   PubMed Web of Science ®Google Scholar
• Wong G, Kobinger G. A strategy to simultaneously eradicate the natural reservoirs of rabies and Ebola virus [Comment]. Expert Rev Vaccines. 2012 Feb;11(2):163–166. PubMed PMID: 22309665; eng. DOI:10.1586/erv.11.179
   PubMed Web of Science ®Google Scholar
• Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. J Virol. 2009 Apr;83(8):3810–3815. PubMed PMID: 19211761; PubMed Central PMCID: PMC2663241. eng. DOI:10.1128/JVI.00074-09
   PubMed Web of Science ®Google Scholar
• Marzi A, Halfmann P, Hill-Batorski L, et al. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t]. Science. 2015 Apr 24;348(6233):439–442. PubMed PMID: 25814063; PubMed Central PMCID: PMC4565490. eng. DOI:10.1126/science.aaa4919
   PubMed Web of Science ®Google Scholar
• Marzi A, Murphy AA, Feldmann F, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection [Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t]. Sci Rep. 2016 Feb 15;6:21674.
   PubMed Web of Science ®Google Scholar
• Enserink M. The Ebola Epidemic. High hopes for Guinean vaccine trial [News]. Science. 2015 Jan 16;347(6219):219–220. PubMed PMID: 25593164; eng. Doi:10.1126/science.347.6219.219
   PubMed Web of Science ®Google Scholar
• Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola Therapeutics During the 2014-2015 Outbreak [Research Support, Non-U.S. Gov’t Review]. Trends Mol Med. 2016 Feb;22(2):164–173. PubMed PMID: 26774636; eng. DOI:10.1016/j.molmed.2015.12.005
   PubMed Web of Science ®Google Scholar
• Tully CM, Lambe T, Gilbert SC, et al. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases [Research Support, Non-U.S. Gov’t Review]. Lancet Infect Dis. 2015 Mar;15(3):356–359. PubMed PMID: 25595637; eng. DOI:10.1016/S1473-3099(14)71071-0
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial [Clinical Trial, Phase I Randomized Controlled Trial Research Support, N.I.H., Intramural Research Support, U.S. Gov’t, Non-P.H.S.]. Lancet. 2015 Apr 18;385(9977):1545–1554. PubMed PMID: 25540891; eng. DOI:10.1016/S0140-6736(14)62385-0
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Lancet. 2015 Jun 6;385(9984):2272–2279. PubMed PMID: 25817373; eng. DOI:10.1016/S0140-6736(15)60553-0
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines: a randomized clinical trial [Clinical Trial, Phase I Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Jama. 2016 Apr 19;315(15):1610–1623. PubMed PMID: 27092831; eng. DOI:10.1001/jama.2016.4218
   PubMed Web of Science ®Google Scholar
• Cooper CL, Bavari S. A race for an Ebola vaccine: promises and obstacles. Trends Microbiol. 2015 Feb;23(2):65–66. S0966-842X(14)00249-2 [pii]. PubMed PMID: 25535021; eng. DOI:10.1016/j.tim.2014.12.005
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N Engl J Med. 2015 Jan 28 PubMed PMID: 25629663; Eng. DOI:10.1056/NEJMoa1411627
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report. N Engl J Med. PubMed PMID: 25426834; Eng Nov 26 2014. 10.1056/NEJMoa1410863.
   PubMed Web of Science ®Google Scholar
• Antoine G, Scheiflinger F, Dorner F, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 1998 May 10;244(2):365–396. PubMed PMID: 9601507; eng. DOI:10.1006/viro.1998.9123
   PubMed Web of Science ®Google Scholar
• Zhou Y, Sullivan NJ. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine [Research Support, N.I.H., Intramural Review]. Curr Opin Immunol. 2015 Aug;35:131–136. PubMed PMID: 26247875; eng. DOI:10.1016/j.coi.2015.06.006
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Goeijenbier M, Moesker FM, et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis. 2014 Dec;14(12):1196–1207. PubMed PMID: 25455987; eng. DOI:10.1016/S1473-3099(14)70963-6
   PubMed Web of Science ®Google Scholar
• Satti I, Meyer J, Harris SA, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Oct;14(10):939–946. PubMed PMID: 25151225; PubMed Central PMCID: PMC4178237. eng. DOI:10.1016/S1473-3099(14)70845-X
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis. 2013 Mar 1;207(5):749–758. PubMed PMID: 23225902; PubMed Central PMCID: PMC3611764. eng. DOI:10.1093/infdis/jis753
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study [Clinical Trial, Phase I Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Lancet Infect Dis. 2016 Mar;16(3):311–320. PubMed PMID: 26725450; eng. DOI:10.1016/S1473-3099(15)00486-7
   PubMed Web of Science ®Google Scholar
• Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis. 2011 Nov;204(Suppl 3):S785–90. PubMed PMID: 21987751; eng. DOI:10.1093/infdis/jir298
   PubMed Web of Science ®Google Scholar
• Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick [Case Reports Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t]. Jama. 2015 Mar 24–31;313(12):1249–1255. PubMed PMID: 25742465; PubMed Central PMCID: PMC4874522. eng. DOI:10.1001/jama.2015.1995
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe [Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. N Engl J Med. 2016 Apr 28;374(17):1647–1660. PubMed PMID: 25830326; eng. DOI:10.1056/NEJMoa1502924
   PubMed Web of Science ®Google Scholar
• Clarke DK, Nasar F, Chong S, et al. Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol. 2014 Jun;88(12):6690–6701. PubMed PMID: 24696472; PubMed Central PMCID: PMC4054374. eng. DOI:10.1128/JVI.03441-13
   PubMed Web of Science ®Google Scholar
• Mire CE, D M, Geisbert JB, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015 Apr 30;520(7549):688–691. PubMed PMID: 25853476; PubMed Central PMCID: PMC4629916. DOI:10.1038/nature14428
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus ebola vaccine - preliminary report. N Engl J Med. 2015 Apr 1 PubMed PMID: 25830322; Eng. DOI:10.1056/NEJMoa1414216
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the safety of and immune response to a human parainfluenza virus type 3 Ebola virus vaccine (HPIV3-EbovZ GP) in healthy adults. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 2016 Mar 29. cited. Available from https://clinicaltrials.gov/ct2/show/NCT02564575.
   Google Scholar
• Kuehn BM. As Ebola epidemic begins to slow, trials of drugs and vaccines speed up [News]. Jama. 2015 Mar 10;313(10):1000–1002. PubMed PMID: 25671623; eng. Doi:10.1001/jama.2015.0942
   PubMed Web of Science ®Google Scholar
• Butler D. Ebola experts seek to expand testing [News]. Nature. 2014 Dec 11;516(7530):154–155. PubMed PMID: 25503213; eng. Doi:10.1038/516154a
   PubMed Web of Science ®Google Scholar
• Caplan AL, Plunkett C, Levin B. Selecting the right tool for the job. PubMed PMID: 25856591; eng Am J Bioeth. 2015;154:4–10. DOI:10.1080/15265161.2015.1010993
   PubMed Web of Science ®Google Scholar
• Janssen Vaccines & Prevention B.V. Staged phase 3 study to assess the safety and immunogenicity of ebola candidate vaccines Ad26.ZEBOV and MVA-BN-Filo during implementation of stages 1 and 2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. cited 2016 Mar 30. Available from. NLM Identifier: NCT02509494 https://clinicaltrials.gov/ct2/show/record/NCT02509494
   Google Scholar
• Mohammadi D. Ebola vaccine trials back on track [News]. Lancet. 2015 Jan 17;385(9964):214–215. PubMed PMID: 25601786; eng. Doi:10.1016/S0140-6736(15)60035-6
   PubMed Web of Science ®Google Scholar
• Gulland A. Ebola vaccine to be tested on 30,000 volunteers [News]. Bmj. 2015;350:h448. PubMed PMID: 25616423; eng. DOI:10.1136/bmj.h448
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Partnership for Research on Ebola Vaccines in Liberia (PREVAIL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 2016 Mar 25. cited. Available from https://clinicaltrials.gov/ct2/show/NCT02344407.
   Google Scholar
• Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials. 2016 Feb;13(1):49–56. PubMed PMID: 26768572; eng. DOI:10.1177/1740774515621037
   PubMed Web of Science ®Google Scholar
• Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). Centers for Disease Control and Prevention. 2015. Available from: http://www.cdc.gov/vhf/ebola/strive/qa.html Last accessed 2017 Nov 8.
   Google Scholar
• Centers for Disease Control and Prevention. STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 2016 Mar 30. cited. Available from https://clinicaltrials.gov/ct2/show/NCT02378753.
   Google Scholar
• Widdowson MA, Schrag SJ, Carter RJ, et al. Implementing an Ebola Vaccine Study - Sierra Leone. MMWR Suppl. 2016 Jul 08;65(3):98–106. PubMed PMID: 27387395; eng. DOI:10.15585/mmwr.su6503a14
   PubMedGoogle Scholar
• Questions and Answers – Ebola Phase III Vaccine Trial in Guinea. World Health Organization. 2015. Available from: http://www.who.int/medicines/ebola-treatment/q_a_vaccine_trial_guinea/en Last accessed 2017 Nov 8
   Google Scholar
• Muller J, Schonfisch B, Kirkilionis M. Ring vaccination [Comparative Study]. J Math Biol. 2000 Aug;41(2):143–171. PubMed PMID: 11039695; eng.
   PubMedGoogle Scholar
• Ebola ça Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. Bmj. 2015 Jul 27;351:h3740. PubMed PMID: 26215666; PubMed Central ID PMCID: PMC4516343; eng. Doi:10.1136/bmj.h3740
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Lancet. 2015 Aug 29;386(9996):857–866. PubMed PMID: 26248676; eng. DOI:10.1016/S0140-6736(15)61117-5
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017 Feb 04;389(10068):505–518. PubMed PMID: 28017403; PubMed Central PMCID: PMC5364328. DOI:10.1016/S0140-6736(16)32621-6
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination [Research Support, N.I.H., Extramural]. Clin Infect Dis. 2012 Jun;54(11):1615–1617. PubMed PMID: 22437237; PubMed Central PMCID: PMC3348952. eng. DOI:10.1093/cid/cis238
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity [Review]. Clin Infect Dis. 2008 Aug 1;47(3):401–409. PubMed PMID: 18558875; eng.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009 May;7(5):393–400. PubMed PMID: 19369954. DOI:10.1038/nrmicro2129
   PubMed Web of Science ®Google Scholar
• Olinger GG Jr., Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030–18035. PubMed PMID: 23071322; PubMed Central PMCID: PMC3497800. eng. DOI:10.1073/pnas.1213709109
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies [Research Support, Non-U.S. Gov’t]. Sci Transl Med. 2012 Jun 13;4(138):138ra81. PubMed PMID: 22700957; eng. DOI:10.1126/scitranslmed.3003876
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Nature. 2014 Oct 2;514(7520):47–53. PubMed PMID: 25171469; PubMed Central PMCID: PMC4214273. eng. DOI:10.1038/nature13777
   PubMed Web of Science ®Google Scholar